 |
|
|
Clare J. TwistAcademic Appointments
Appointment
Organization
Assistant Professor - Med Center Line
|
Professional Education
Degree
Awarding Institution
Field of Study
Year of Graduation
Fellowship
Children's Hospital, Boston/DFCI
Pediatric Hematology & Oncology
1993
Residency
Children's Memorial Hospital
Pediatrics
1990
M.D.
Albany Medical College
Medicine
1987
M.S.
SUNY Buffalo
Immunology
1984
B.S.
University of Notre Dame
Pre-professional
1982
Research Interests
My primary research interest is in the study and treatment of neuroblastoma. My clinical interests also include Wilms tumor, hepatoblastoma, post-transplant lymphoproliferative disorders, phase I therapies for hematologic malignancies, as well as palliative and end of life care.
As a clinical investigator in the Children's Oncology Group (COG), I am involved in the clinical trial design of treatment protocols for patients with neuroblastoma, and am the Study Chair for the current COG Phase III Study for the treatment of children with Intermediate Risk Neuroblastoma. I am also the Principal Investigator at Stanford for the New Advances in Neuroblastoma (NANT) Consortium, a limited institution consortium which develops Phase I trials of novel therapies for patients with high risk and recurrent neuroblastoma. I am also interested in new therapies for the treatment of hematologic malignancies and am the Principal Investigator at Stanford for the Therapeutic Advances in Childhood Leukemia (TACL) Consortium, another limited institution consortium specifically dedicated to the development of novel therapies for relapsed leukemias.
As a clinical investigator in the Children's Oncology Group (COG), I am involved in the clinical trial design of treatment protocols for patients with neuroblastoma, and am the Study Chair for the current COG Phase III Study for the treatment of children with Intermediate Risk Neuroblastoma. I am also the Principal Investigator at Stanford for the New Advances in Neuroblastoma (NANT) Consortium, a limited institution consortium which develops Phase I trials of novel therapies for patients with high risk and recurrent neuroblastoma. I am also interested in new therapies for the treatment of hematologic malignancies and am the Principal Investigator at Stanford for the Therapeutic Advances in Childhood Leukemia (TACL) Consortium, another limited institution consortium specifically dedicated to the development of novel therapies for relapsed leukemias.
Publications
- Bieber MM, Twist CJ, Bhat NM, Teng NN "Effects of human monoclonal antibody 216 on B-progenitor acute lymphoblastic leukemia in vitro." Pediatr Blood Cancer 2006; More »
- O'brien MM, Lee-Kim Y, George TI, McClain KL, Twist CJ, Jeng M "Precursor B-cell acute lymphoblastic leukemia presenting with hemophagocytic lymphohistiocytosis." Pediatr Blood Cancer 2006; More »
- Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Eickhoff J, Seeger RC, Matthay KK, Reynolds CP, Twist C, Krailo M, Adamson PC, Reisfeld RA, Gillies SD, Sondel PM "A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group." Clin Cancer Res 2006; 12: 6: 1750-9 More »
- London WB, Boni L, Simon T, Berthold F, Twist C, Schmidt ML, Castleberry RP, Matthay KK, Cohn SL, De Bernardi B "The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives." Cancer Lett 2005; 228: 1-2: 257-66 More »
- Twist CJ, Link MP "Assessment of lymphadenopathy in children." Pediatr Clin North Am 2002; 49: 5: 1009-25 More »
10 publications: view full list
